AWAK Technologies Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AWAK Technologies Inc. - overview
Established
2007
Location
Singapore, -, Singapore
Primary Industry
Medical Devices & Equipment
About
AWAK Technologies Inc. , based in Singapore, develops innovative solutions for kidney care, focusing on enhancing patient outcomes through advanced dialysis technologies. Founded in 2007 by Kok Neo, AWAK Technologies Inc. specializes in kidney care technology.
The company is headquartered in Singapore and has pursued multiple funding rounds to support its operations and product development. The most recent funding took place in September 2023, where the company raised USD 2. 50 mn in a Series B round, co-led by Lion X Ventures and Vickers Venture Partners, with additional investments from Advanced MedTech Holdings and Eckuity. To date, AWAK Technologies has participated in 4 deals, accumulating a total of USD 2.
50 mn in funding, with a current valuation of USD 141. 89 mn. AWAK Technologies offers a range of kidney care solutions that address the challenges of chronic kidney disease. Key products include the Viva Komfort for point-of-care dialysis fluid generation and infection management, the ultraportable Viva Kompact for on-the-go dialysis, and the Viva Konnect, which integrates digital and AI technology for remote patient monitoring.
These innovations are designed primarily for healthcare facilities and patients across North America, Europe, and parts of Asia, targeting the global public health issue of kidney disease affecting one in ten individuals. In the most recent fiscal year of 2019, AWAK Technologies reported zero revenue, with an EBITDA loss of USD 13,848,388. 30 for the year 2023. The company's revenue model is based on direct sales and partnerships with healthcare institutions, facilitating transactions through procurement agreements for their products such as Viva Komfort and Viva Kompact.
In September 2023, AWAK Technologies Inc. successfully raised USD 2. 50 mn in Series B funding, which will be allocated to support ongoing clinical trials and facilitate the company's entry into the US market. The company is committed to developing new products to enhance kidney care and is actively planning to expand its reach into new markets, particularly focusing on the US healthcare sector by the end of 2024.
Current Investors
SEEDS Capital, Vickers Venture Partners, Baxter International, Inc.
Primary Industry
Medical Devices & Equipment
Sub Industries
Healthcare IT, Medical Devices & Equipment, Application Integration Software
Website
www.awak.com
Verticals
HealthTech, Manufacturing, Wearables & Quantified Self
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.